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INTRODUCTORY PARAGRAPH 
Human leukocyte antigen (HLA) genes are strongly associated with risk of 
autoimmune diseases. While current models commonly assume log-additive effects, 
we speculated that differences in autoantigen binding repertoires between a 
heterozygote’s two expressed HLA variants may result in non-additive risk effects. 
We tested non-additive disease contributions of classical HLA alleles in 25,835 
patients with rheumatoid arthritis (RA), type 1 diabetes (T1D), psoriasis vulgaris 
(PsV), idiopathic achalasia (Ach) or celiac disease (CeD), and matched controls. In 
four out of the five common autoimmune diseases, we observed highly significant 
non-additive terms (RA: P = 2.5x10
-12; T1D: P = 2.4x10-10; PsV: P = 5.9x10-6; CeD: P 
= 1.2x10-87). In three of these diseases, the non-additive terms were explained by 
interactions between specific classical HLA alleles (RA: P = 1.8x10-3, T1D: P = 
8.6x10-27; CeD: P = 6.0x10-100), as opposed to dominance effects. These interactions 
generally increased disease risk and explained an additional 1.4% of phenotypic 
variance in RA, 4.0% in T1D, and 4.1% in CeD, beyond a simple additive model.  
 
MAIN TEXT 
Genetic variation within HLA genes, as part of the major histocompatibility complex 
(MHC), is associated with many autoimmune diseases, including rheumatoid arthritis 
and multiple sclerosis1-3. For these diseases, the MHC explains more phenotypic 
variance than any other locus does. Previous research has shown non-additive 
effects (e.g. overdominance) at classical MHC genes in resistance to infectious 
diseases4-7, and researchers have proposed that non-additive effects may also occur 
in autoimmune diseases8-12. Indeed, some studies have reported synergistic 
interactions between certain HLA haplotypes13-15, but non-additive effects and 
Lenz, Deutsch, et al.  Non-additive effects in HLA 
interactions have not been systematically characterized in large cohorts and across 
multiple independent diseases. 
 
In an additive model, the effects of two risk alleles combine linearly on the log-odds 
scale; non-additive effects arise from interactions between two alleles, or from 
intrinsic effects of individual alleles (e.g. due to haploinsufficiency)16,17. Since both 
alleles at a given HLA locus are expressed, heterozygous genotypes might confer 
expanded antigen binding properties and elevated autoantigen presentation, 
depending on the degree of complementarity between the two alleles18. As a result, 
interactions between HLA alleles (within the same locus or across separate loci) can 
yield non-additive effects.  
 
In order to test for the presence of non-additive effects, we used SNP2HLA19 to 
impute HLA alleles from dense ImmunoChip-based SNP genotype data in five 
autoimmune diseases: seropositive rheumatoid arthritis (RA, Ncases/controls = 
5,337/11,049)20,21, type 1 diabetes (T1D, N = 5,567/6,265)22, psoriasis vulgaris (PsV, 
N = 3,089/5,964)23, idiopathic achalasia (Ach, N = 727/2,911)24, and celiac disease 
(CeD, N = 11,115/9,042)25 (Supplementary Table S1). We demonstrated accurate 
HLA imputation elsewhere19 using the ImmunoChip platform and the same reference 
panel (T1D Genetics Consortium, N = 5,225)26.  
 
Based on recent studies that fine-mapped HLA associations to these five diseases, 
we focused our analyses of non-additive effects on four-digit classical alleles at the 
HLA loci with the strongest effects (RA: HLA-DRB1, T1D: HLA-DRB1-DQA1-DQB1, 
PsV: HLA-C, Ach: HLA-DQA1-DQB1, CeD: HLA-DQA1-DQB1). Since T1D, Ach, and 
CeD have independent associations to multiple, linked HLA genes22,24,25, we 
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combined phased four-digit classical alleles from separate genes into multi-locus 
haplotypes for these diseases. For our primary test, we restricted our analysis to 
common alleles at each locus (reference panel allele frequency > 5%; 
Supplementary Table S2) and to individuals carrying only these common alleles 
(“common allele dataset”, Supplementary Table S1). This approach ensured the 
highest imputation accuracy, and it increased the statistical power to estimate the 
true additive component of each haplotype by providing a sufficient number of 
homozygote events. As a secondary test, we analyzed both rare and common 
haplotypes that were present in at least 10 homozygous individuals (“full dataset”, 
Supplementary Table S1). 
 
To assess for non-additive associations, we first examined disease risk of 
homozygotes and heterozygotes for each haplotype. Under additivity, the log-odds of 
heterozygotes should be half that of homozygotes. However, we found that many 
haplotypes deviated from this linear relationship (Figure 1a). We also observed an 
excess of heterozygous genotypes outside of Hardy-Weinberg equilibrium in cases 
(Figure 1b), but not controls (Figure 1c). In contrast, 44 RA-associated non-MHC 
SNPs27 followed an additive relationship perfectly (Figure 1d) and also followed 
Hardy-Weinberg equilibrium (Figure 1e). We note that the lower effect sizes of non-
MHC variants may limit our ability to detect non-additive effects.  
 
To test for the general presence of non-additive effects, we constructed one logistic 
regression model for each disease with additive and dominance terms for all common 
haplotypes (Figure 2a)28. Strikingly, for four of the five diseases, the inclusion of 
dominance terms improved the fit of the models (RA: Pdf=5 = 2.5x10
-12; T1D: Pdf=5 = 
2.4x10-10, PsV: Pdf=7 = 5.9x10
-6; CeD: Pdf=6 = 1.2x10
-87). In the achalasia dataset we 
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observed a non-significant trend (Pdf=5 = 0.066); power may have been limited due to 
the relatively small sample size of this dataset. These results were consistent in the 
full datasets, including a larger set of common and rare alleles (Supplementary 
Table S3). In a purely additive model, common HLA haplotypes explained 8.1% of 
phenotypic variance for RA, 13.3% for T1D, 5.9% for PsV, and 21.1% for CeD. The 
addition of dominance terms explained an additional 0.9%, 1.1%, 0.9%, and 1.9% of 
phenotypic variance, respectively (Figure 2b). These values are comparable to the 
effect of the largest known non-MHC RA risk effect; the rs2476601 PTPN22 risk 
allele explains 0.8% of the total phenotypic variance in RA29.  
 
When we examined non-additive effects of individual HLA haplotypes separately, we 
observed that most haplotypes showed significant non-additive contributions in RA, 
T1D, and CeD (Table 1, Supplementary Table S6). In contrast, of 7 common 
haplotypes tested in PsV, only HLA-C*06:02 showed a non-additive effect. Across all 
four diseases, 14 of 23 HLA haplotypes showed non-additivity, and 12 had a positive 
dominance component; thus, for most alleles, heterozygosity confers a higher risk of 
autoimmunity than expected from homozygote disease risk (Figure 2c).  
 
We considered the possibility that the observed non-additive effects might have 
arisen from imputation artifacts. In order to ensure high quality imputation, we only 
used samples genotyped on ImmunoChip, which contains dense SNP coverage 
(>5,000 SNPs within the MHC)19. We also imputed cases and controls together, to 
ensure consistent imputation quality across all samples. Additionally, our primary 
analyses focused on common alleles that were well represented in the reference 
panel and had high imputation confidence (INFO) scores30 (>0.973, median 1.003, 
Supplementary Table S2). We note that P-values for non-additive effects were 
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unrelated to INFO scores (Kendall’s tau = -0.08, P = 0.56; Supplementary Fig. S1). 
Finally, we conducted a stringent permutation analysis where we reassigned case-
control status, based on an additive risk model for HLA haplotypes, and then 
assessed if non-additive effects were spuriously observed. This approach conserved 
the additive effect of each haplotype (Supplementary Figure S3) and 
simultaneously maintained any imputation inaccuracies within the dataset. Across all 
four diseases with significant non-additive effects, the fit of the dominance model in 
10,000 trials never exceeded the fit observed in the actual data (Supplementary 
Figure S4). These results argue that our findings cannot be explained by imputation 
artifacts. 
 
In RA, T1D, and Ach, the strongest additive disease associations point to individual 
amino acids (rather than four-digit classical alleles)20,22,24. Nonetheless, non-additive 
haplotype effects remained significant even after controlling for the non-additive 
effects of individual amino acids (Supplementary Note S1).  
 
We then investigated whether interactions between specific haplotypes might explain 
the non-additive dominance effects; interactions are present when disease risk for 
specific pairs of haplotypes deviates from a linear relationship. We defined a logistic 
regression model that included first-order interaction terms between all common 
haplotypes within a given locus. For three diseases (RA, T1D, and CeD), which are 
most strongly associated with HLA class II genes, the model with additive terms and 
interaction terms showed a significant improvement in fit, compared to a model with 
additive and dominance terms (RA: Pdf=5 = 1.8x10
-3, T1D: Pdf=5 = 8.6x10
-27; CeD: Pdf=9 
= 6.0x10-100). Hence, the observed non-additive effects for RA, T1D, and CeD are at 
least partially explained by interactions between HLA haplotypes. The models with 
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additive and interaction terms explained 9.45%, 17.31%, and 25.22% of phenotypic 
variance for RA, T1D, and CeD, respectively; interactions yielded an additional 
0.46%, 2.94%, and 2.25% of phenotypic variance over a model with additive and 
dominance terms (Figure 2b).  
 
In contrast, PsV (most strongly associated with a HLA class I gene, HLA-C) showed 
no evidence of interactions (Pdf=14 = 0.92). In order to further identify interactions, we 
imputed an additional 5,294 psoriasis cases and 10,295 controls genotyped on 
platforms other than ImmunoChip (Supplementary Table S1c). While this increased 
our sample size dramatically, we still observed no evidence of interactions (Pdf=14 = 
0.87; Supplementary Table S10). The contrast between PsV and other diseases 
may be related to recent suggestions that the PsV association with HLA-C*06:02 is 
caused by variation in an HLA-C*06:02 expression-controlling enhancer element31, 
rather than antigenic binding properties. Ach showed no evidence for interaction 
effects in our primary analysis (Pdf=5 = 0.15), and only nominal evidence when we 
tested the full dataset with common and rare haplotypes. All other diseases yielded 
qualitatively identical results when we tested the full datasets with both rare and 
common haplotypes (Supplementary Table S3). 
 
We then identified the specific HLA haplotypes contributing to interaction effects in 
RA, T1D, and CeD. For RA, 7 of the 10 possible interactions were significant 
(P<0.005=0.05/10), and all increased disease risk beyond the separate additive 
contribution of each haplotype (Table 2, Fig. 3a). For T1D, 7 of 10 interactions were 
significant (P<0.005=0.05/10), with five increasing risk and two reducing risk 
(Supplementary Table S8, Supplementary Figure S5); these interactions are 
detailed elsewhere and are included here for completeness22. For CeD, among the 
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15 possible haplotype pairs, there were four significant pairwise interactions 
(P<0.003=0.05/15), each increasing risk (Table 2, Fig. 3b). The identified 
interactions refined our previous findings of non-additive disease contributions. For 
instance, in CeD, DQA1*05:01-DQB1*02:01 had a significant non-additive 
component (P = 4.7x10-19) with d > 0, indicating an elevated disease risk in 
heterozygotes. This elevated disease risk is explained by the interaction model, in 
which we observed significant risk-increasing interactions between DQA1*05:01-
DQB1*02:01 and three other alleles (Fig. 3b).  
 
Our results build on previous studies that proposed specific non-additive associations 
in different autoimmune diseases. While previous studies of heterozygote risk in RA 
focused on haplotypes with a common 'shared epitope' (SE) at positions DRβ1#70-
7432,33, we discovered significant interactions between SE haplotypes and non-SE 
haplotypes. There was no evidence for a previously reported interaction between 
DRB1*04:01 and DRB1*04:0434 (Supplementary Note S2). A few specific 
interactions in T1D have been described previously, such as an elevated disease risk 
for HLA-DRB1*03-DQB1*02/DRB1*0401-DQB1*0302 genotypes15. Our recent 
comprehensive investigation of T1D also confirmed this interaction and revealed 
additional interactions with both increasing and decreasing risk effects22. 
 
In CeD, the DQ2.5 haplotype, consisting of the combination of HLA-DQA1*05:01 and 
HLA-DQB1*02:01, is the primary contributor to CeD susceptibility35,36. Here, we 
confirmed that DQA1*05:01-DQB1*02:01 has the strongest disease association in an 
additive model (P = 4.3x10-675), and we also found significant interactions between 
DQA1*05:01-DQB1*02:01 and other haplotypes. Some of these combinations 
contained DQA1*05:01 and DQB1*02:01 in trans, but we also observed haplotype 
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combinations that have not previously been implicated (e.g. DQA1*05:01-
DQB1*02:01/DQA1*01:01-DQB1*05:01; OR = 3.74, P = 1.9x10-10). Interestingly, the 
interaction with the strongest risk effect in our data (DQA1*02:01-
DQB1*02:02/DQA1*05:01-DQB1*03:01; OR = 16.85, P = 7.0x10-74), identified in 
previous studies37, contained the protective haplotype DQ7 (coded by DQA1*05:01-
DQB1*03:01; homozygote OR = 0.03), highlighting the complexity of interactions in 
the HLA.  
 
Interestingly, we note that there was little overlap between diseases in the pairs of 
haplotypes with significant interactions, suggesting that the precise interactions are 
disease specific. These interactions may depend on the exact autoantigens driving 
disease susceptibility2. Such a scenario would be consistent with previous 
observations, in particular in RA, where specific T and B cell reactions against 
different citrullinated autoantigens seem to be restricted by different HLA-DR variants 
involving different immune effector functions38,39. Similarly, in CeD, where the major 
disease antigen is known, expression of the gluten peptide-presenting HLA-DQ2.5 
variant is the primary determinant of disease risk, which can be formed by genotypes 
carrying HLA-DQA1*05:01 and HLA-DQB1*02:01 in trans, explaining the observed 
interaction effect between these haplotypes36. Another possibility is that differential 
intrinsic stability of certain trans-heterodimers may also affect disease risk, as 
suggested for HLA-DQ in T1D40. Further investigations of causal mechanisms are 
needed to precisely understand how interacting alleles confer genetic predisposition 
for these complex diseases.  
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METHODS 
 
Samples 
We analyzed genotype data from previously published studies of HLA association in 
anti-citrullinated protein antibody positive (ACPA+) rheumatoid arthritis (RA, N = 
16,386)21, type 1 diabetes (T1D, N = 11,832)22, psoriasis vulgaris (PsV, N = 9,053)23, 
idiopathic achalasia (Ach, N = 3,638)24, and celiac disease (CeD, N = 20,157)25. 
Each dataset contained samples from multiple case-control GWAS cohorts, and all 
individuals had European ancestry (Supplementary Table S1).   
 
HLA genotypes and imputation quality 
The SNP genotype data for the MHC region, obtained from previous disease-specific 
studies (see above), was generated by the Illumina ImmunoChip platform41. 
Following previous studies, we defined the MHC region as the region on 
chromosome 6 from 29Mb to 34Mb. Stringent quality control was conducted following 
the disease-specific studies described above. We imputed four-digit classical HLA 
alleles with SNP2HLA19, using dense SNP data across the MHC region for each 
disease dataset (number of SNPs used for imputation for RA: 4,499; for T1D: 4,604; 
PsV: 4,030; for Ach: 3,773; and for CeD: 3,249) and a reference panel of 5,225 
individuals of European ancestry from the Type 1 Diabetes Genetics Consortium 
(T1DGC)26. We have separately demonstrated high imputation accuracy using 
genotype data from the ImmunoChip platform19.  
 
For each allele, the INFO score was calculated from the ratio of the observed 
variance in dosage to the expected variance under Hardy-Weinberg equilibrium30:  
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 (Equation 1) 
where x is the imputed dosage and p is the frequency of the allele. An INFO score 
close to 0 indicates poor imputation quality, while a score closer to 1 indicates higher 
quality; a value greater than 1 is also possible. Due to the presence of non-additive 
effects that inflated the disease risk in heterozygotes, the allele distribution in disease 
cases deviated from Hardy-Weinberg equilibrium. Therefore, we calculated INFO 
scores using the variance and allele frequency in controls only (Supplementary 
Table S2). However, because the imputation algorithm does not take case/control 
status into account, we expected that imputation quality should be similar in cases 
and controls. For RA, we also calculated INFO scores within each cohort to test 
whether lower INFO scores (i.e. lower quality of imputed genotypes) were associated 
with a higher likelihood to detect non-additive effects, which could suggest that non-
additive effects are an artifact of imputation errors.  
 
Selection of genes for analysis 
For each disease, we selected the HLA genes that were most significantly associated 
with disease risk in previous studies (RA: HLA-DRB121; T1D: HLA-DRB1, HLA-
DQA1, HLA-DQB122; PsV: HLA-C23; Ach: HLA-DQA1, HLA-DQB124; CeD: HLA-
DQA1, HLA-DQB125). For diseases in which more than one HLA gene was 
implicated to confer major independent risk contribution, we defined haplotypes 
according to unique combinations of four-digit classical alleles at each relevant gene. 
We used phased best guess genotypes from SNP2HLA to ensure that each 
haplotype contained classical alleles on the same chromosome.  
 
 
I N F O
v a r (x)
2(p) (1 p)
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For RA and PsV, we repeated the analysis using imputed dosages (which range on a 
continuous scale from 0-2) rather than best guess genotypes (which are restricted to 
the integer values 0, 1, or 2; see Supplementary Table S5). Because imputed 
dosages do not contain phasing information, we did not perform this analysis for the 
diseases involving multiple genes. 
 
Selection of alleles for analysis  
We performed all association tests with two datasets: the common allele dataset and 
the full dataset. In the common allele dataset, we restricted our analysis to classical 
alleles with a frequency greater than or equal to 5% in the T1DGC reference panel, 
or haplotypes comprising these classical alleles (RA: m = 5; T1D: m = 5; PsV: m = 7; 
Ach: m = 5; CeD: m = 6; where m indicates the number of included HLA 
alleles/haplotypes). This cutoff ensured a very high imputation quality, and INFO 
scores for all alleles in the common allele subset exceeded 0.97 (Supplementary 
Table S2). We also ensured that all haplotypes in the common subset had at least 10 
homozygous individuals. (If fewer than 10 homozygotes are present, the additive and 
non-additive terms are statistically indistinguishable.) In the full dataset, we included 
all m variants (four-digit classical alleles or haplotypes) with at least 10 homozygous 
individuals (RA: m = 11; T1D: m = 11; PsV: m = 13; Ach: m = 9; CeD: m = 10).   
 
We ensured complete data in both datasets by excluding all individuals who lacked 
exactly two best-guess alleles at a given locus. For analyses that used imputed 
dosages, we excluded all individuals whose total dosage across the relevant alleles 
was less than 1.95 or greater than 2.05. 
 
Statistical framework for association testing 
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To analyze the effects of HLA haplotypes on disease risk, we used a logistic 
regression framework. We began by presenting a baseline model, consistent with the 
models used to fine-map HLA effects in previous recent publications for RA21, T1D22, 
PsV23, Ach24, and CeD25. These models assume a purely additive contribution from 
each haplotype. To control for cohort-specific effects and population stratification, we 
included an indicator variable for each cohort, the first L principal components (for 
RA, PsV, and Ach), and a gender term (for T1D and CeD) as covariates. This 
resulted in the following logistic regression model:  
  
(Equation 2) 
where  is the logistic regression intercept, aj is the additive effect of allele j, and xi,j is 
the allelic dosage (using best guess genotype or imputed dosage) of allele j in 
individual i. For a multi-allelic locus with m possible alleles, we included m – 1 a 
parameters, and we set the final a parameter to 0 to denote the reference allele. We 
arbitrarily selected the most common allele in the controls as the reference allele. 
The parameter i,k is a binary indicator variable that equals 1 if and only if individual i 
is in cohort k, and k is the effect for the k
th cohort. Among a total of K cohorts, we 
arbitrarily selected the largest cohort as the reference cohort and set its  parameter 
to 0.  
 
For RA, PsV, and Ach, we also included the first L principal components, where pi,k,l 
is the value of principal component l in cohort k for individual i, and k,l is the 
corresponding effect size. To be consistent with HLA fine mapping studies on other 
diseases, we used L = 10 for RA21 and PsV23, L = 5 for Ach24, and no principal 
components for T1D22 or for CeD25.  
 

log(odds
i
)    a
j
j 1
m1
 x i, j   i,k
k1
K
 (k   k,l pi,k,l )  gi
l1
L

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We included an additional covariate to account for gender differences in T1D and 
CeD, once again to conform to previous HLA fine-mapping analyses22,25. Here,  is 
the effect of gender, and gi is a binary indicator variable that equals 1 if and only if 
individual i is female. We did not include the gi parameter for RA, PsV, or Ach, 
following refs. 21,23, and 24, respectively.  
 
We tested significance in fit for each model by calculating the change in deviance 
(defined as -2  the difference in log likelihood) from the original model to the revised 
model. This value follows a 2 distribution with n degrees of freedom, where n is the 
number of new parameters introduced in the revised model. For the additive model, n 
is 1 less than the total number of tested haplotypes (to account for a reference 
haplotype).  
 
Analysis of dominance and interaction effects 
For each disease, we tested for non-additive effects by including a dominance term dj 
for each represented haplotype in the relevant dataset (the common allele subset or 
the full dataset): 
 
(Equation 3) 
where dj represents the dominance effect of allele j, and xi,j denotes that individual i 
is heterozygous for haplotype j. For analyses involving best guess genotypes, xi,j if 
and only if xi,j  = 1. For dosage-based analyses, we used the formula xi,j = 1 – abs(1 – 
xi,j). We assessed the change in deviance between the additive model and the 
dominance model, which follows a 2 distribution with m degrees of freedom (1 for 
each haplotype). To determine the relative non-additive effect of a specific haplotype, 
we constructed a separate model for each haplotype by repeating the model in 

lo g (o d d s
i
)    a
j
j 1
m 1
 x i, j  d j x i , j 
j 1
m
  i,k
k 1
K
 ( k   k , l p i,k , l )  g i
l 1
L

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equation 3 for a single value of j (1 degree of freedom). For the single-haplotype 
models, we used a significance threshold of P < 0.05/m to correct for multiple tests.  
 
We also constructed an interaction model, which contains an additive term for each 
haplotype and an interaction term between each pair of haplotypes: 
 
(Equation 4) 
where j,h is effect size of the interaction between alleles j and h. We did not include 
dominance terms in this model, due to partial redundancy between dominance and 
interaction terms. The interaction model contains an additional m(m – 1)/2 degrees of 
freedom (1 for each pairwise interaction), compared to the additive model. We 
assessed the change in deviance between the dominance model and the interaction 
model, which follows a 2 distribution with m(m – 1)/2 – m degrees of freedom. To 
determine the relative significance of individual interaction terms, we compared the 
P-values associated with each  parameter, and we used a significance threshold of 
P < 0.05 / [m(m – 1)/2]. 
 
To compare the disease risk in homozygotes and heterozygotes, we constructed 
additive models after excluding all homozygous individuals (to estimate the 
heterozygous effect size) or excluding all heterozygous individuals (to estimate the 
homozygous effect size). For dosage-based analyses, we defined heterozygous 
individuals as those with a dosage greater than 0.95 and less than or equal to 1.05, 
while homozygous individuals were those with a dosage greater than 1.05. 
 
Calculation of phenotypic variance explained 

lo g (o d d s
i
)    a
j
j 1
m 1
 x i, j   j ,h x i, j x i,h
h  j 1
m
 
j 1
m
  i,k
k 1
K
 (k   k,l pi,k,l )  gi
l 1
L

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We separately calculated the percent of phenotypic variance explained at each locus, 
as described previously20,42. We used a model based on the biometrical model from 
Fisher43 and the liability threshold model from Pearson and Lee44. We assumed that 
disease risk is the consequence of an underlying liability score that is normally 
distributed with a mean of zero and a variance of one, and that individuals with a 
score above a pre-specified threshold get disease45. We determined the thresholds 
by assuming the following prevalence for each disease: RA = 0.5%46, T1D = 0.4%47, 
PsV = 2%48, Ach = 0.01%24, and CeD = 1%35. We also assumed that genetic factors 
can alter these thresholds.  
 
To investigate the percent variance explained by a single locus, we determined the 
prevalence of disease for individuals with each possible genotype, which is 
approximately equal to the population frequency multiplied by the effect size of the 
given genotype. We then determined the corresponding change in the liability score 
threshold for each genotype. The distance between the thresholds represents the 
change in the genotypic means, and we calculated the variance attributable to the 
locus by taking the average squared difference in means, weighted by genotypic 
frequency. For each allele, we assumed that the population frequency was equal to 
the average control frequency. We assumed that the effect size of each genotype 
was the odds ratio derived from one of the three models used in our study: the 
additive model, the additive plus non-additive model, or the additive plus interactions 
model (for RA, T1D, and CeD only).  
 
Analysis of amino acid-level non-additive effects 
For RA, we also analyzed non-additive effects of individual amino acid positions 
within specific HLA genes. We used imputed amino acid genotypes at positions 13, 
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71, and 74 of HLA-DRB1, and we analyzed all residues at these positions with a 
frequency greater than or equal to 5% in the T1DGC reference panel. We used the 
previously described allele-level models (Equations 2 and 3) to assess the non-
additive effects of amino acid variants.  
 
Because amino acid positions within a given locus are very tightly linked, we used a 
stepwise conditioning approach to test the effects at successive positions on RA risk, 
following refs. 20,49. We analyzed positions in the order of significance of additive 
contribution to disease risk. First, we analyzed non-additive effects in DRB1-13. 
Then, we analyzed DRB1-71 while conditioning on DRB1-13, and we analyzed 
DRB1-74 while conditioning on DRB1-13 and DRB1-71. To condition on a specific 
amino acid position, we included all possible amino acid variants at that position as 
covariates, but we excluded any variant that had strong correlations to other variants 
in the dataset (R2 > 0.97)23. 
 
Permutation of imputed HLA genotypes 
To verify that the observed non-additive effects were not a subtle artifact of 
imputation inaccuracies, we permuted SNP-imputed HLA genotypes across cases 
and controls, based on the case probability predicted by a purely additive model 
(Equation 2). This approach conserves allele frequencies (which confer additive 
disease associations) within cases and controls and also conserves individual 
genotypes. However, it randomizes the distribution of homozygote and heterozygote 
genotypes among cases and controls. We performed 10,000 permutations, and for 
each permutation we recorded the deviance of a non-additive model with dominance 
terms for all relevant HLA haplotypes (Equation 3). To validate the permuted 
cohorts, we also compared the distribution of additive effects for each relevant HLA 
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haplotype with the observed values in the actual dataset (Supplementary Figure 
S3). 
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Tables 
Table 1 
Disease Loci Additive model Non-additive model (add. + non-add. component) 
H
L
A
-C
 
H
L
A
-D
R
B
1
 
H
L
A
-D
Q
A
1
 
H
L
A
-D
Q
B
1
 
P OR 95% CI P Heterozygote effect Homozygote effect 
OR 95% CI OR 95% CI 
RA  01:01   1.6x10
-22
 1.54 (1.41-1.68) 1.3x10
-8
 1.77 (1.61-1.96) 1.17 (0.87-1.58) 
  04:01   2.0x10
-206
 3.31 (3.05-3.59) 1.4x10
-7
 3.93 (4.36-8.34) 8.34 (6.87-10.12) 
  03:01   1.2x10
-51
 0.50 (0.45-0.55) 8.6x10
-4
 0.54 (0.61-0.15) 0.15 (0.10-0.22) 
  15:01   7.7x10
-43
 0.55 (0.51-0.60) 1.2x10
-3
 0.60 (0.67-0.21) 0.21 (0.15-0.28) 
T1D  07:01 02:01 02:02 4.2 x10
-50
 0.38 (0.33-0.43) 1.9x10
-5
 0.32 (0.28-0.37) 0.31 (6.39-9.01) 
  04:01 03:01 03:01 2.2x10
-167
 0.18 (0.16-0.21) 3.4x10
-5
 0.20 (0.18-0.23) 0.004 (0.001-0.018) 
  04:01 03:01 03:02 5.4x10
-224
 6.09 (5.38-6.90) 3.5x10
-5
 6.72 (5.88-7.68) 13.86 (8.79-21.86) 
  03:01 05:01 02:01 5.2x10
-35
 1.70 (1.56-1.85) 3.5x10
-3
 1.92 (1.71-2.16) 2.55 (2.12-3.08) 
PsV 06:02    1.5x10
-92
 2.94 (2.65-3.28) 4.9x10
-8
 3.49 (3.09-3.95) 4.28 (3.11-5.87) 
CeD   02:01 02:02 1.3 x10
-67
 1.86 (1.73-1.99) 6.7x10
-62
 2.36 (2.18-2.55) 0.36 (0.27-0.50) 
   05:01 03:01 5.3x10
-156
 0.35 (0.32-0.38) 3.0x10
-25
 0.42 (0.39-0.46) 0.03 (0.02-04) 
   05:01 02:01 4.3x10
-675
 5.78 (5.38-6.20) 4.7x10
-19
 7.28 (6.67-7.95) 22.80 (19.43-26.75) 
   03:01 03:02 8.5x10
-67
 0.50 (0.46-0.54) 3.5x10
-11
 0.43 (0.39-0.47) 0.55 (0.42-0.73) 
   01:01 05:01 4.0x10
-216
 0.27 (0.25-0.29) 3.2x10
-6
 0.29 (0.26-0.32) 0.02 (0.01-0.04) 
 
Table 1: Effect sizes of common HLA haplotypes with significant non-additive effects. Additive and non-additive effect 
sizes are shown for all haplotypes with significant non-additive disease contribution in RA (HLA-DRB1), T1D (HLA-DRB1-
DQA1-DQB1), PsV (HLA-C), and CeD (HLA-DQA1-DQB1). For diseases associated with multiple HLA loci, linked classical 
alleles across those loci were analyzed as haplotypes. P-values indicate the significance of improvement in fit by haplotype-
specific models after sequentially including the additive and the non-additive term for a given haplotype. Odds ratios (OR) 
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and 95% confidence intervals (CI) are given for a purely additive scenario and for a non-additive scenario, in which 
heterozygotes and homozygotes have separate effects. Haplotypes are ordered by significance of the non-additive effect 
within each dataset.  
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Table 2  
(a) RA 
 
DRB1 01:01 03:01 04:01 07:01 15:01 
DRB1 Additive OR 1.96 0.84 3.84 0.82 1.00 (Ref) 
15:01 1.00 (Ref) 
2.06 
(1.6x10
-7
) 
1.50  
(0.02) 
1.43 
(1.8x10
-3
) 
1.27  
(0.20) 
07:01 0.82 
2.02 
(8.9x10
-6
) 
1.03 
(0.89) 
1.49 
(3.6x10
-3
) 
  
04:01 3.84 
1.87 
(2.9x10
-8
) 
1.92 
(5.2x10
-7
) 
 
  
03:01 0.84 
1.63 
(2.2x10
-3
) 
  
 
 
01:01 1.96     
 
 
 
(b) CeD 
 
DQA1- 
DQB1 
01:01 
05:01 
02:01 
02:02 
03:01 
03:01 
03:01 
03:02 
05:01 
02:01 
05:01 
03:01 
DQA1- 
DQB1 
Additive OR 0.86 2.76 0.79 4.53 13.03 1.00 (Ref) 
05:01 
03:01 
1.00 (Ref) 
1.14 
(0.67) 
16.85 
(7.0x10
-74
) 
2.04 
(0.12) 
0.98 
(0.91) 
2.05 
(2.2x10
-7
) 
05:01 
02:01 
13.03 
3.74 
(1.9x10
-10
) 
4.36 
(2.4x10
-44
) 
0.71 
(0.37) 
0.79 
(0.03) 
  
03:01 
03:02 
4.53 
1.08 
(0.75) 
1.23 
(0.15) 
1.05 
(0.90) 
   
03:01 
03:01 
0.79 
1.42 
(0.51) 
1.53 
(0.32) 
 
 
  
02:01 
02:02 
2.76 
1.08 
(0.77) 
   
 
 
01:01 
05:01 
0.86      
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Table 2: Interaction effects among HLA haplotypes. Pairs of common haplotypes 
with significant interaction effects are shown for (a) RA (HLA-DRB1) and (b) CeD (HLA-
DQA1-DQB1). The odds ratio (OR) is displayed for each interaction, and the P-value 
associated with each odds ratio is shown in parentheses. Additive ORs are also 
displayed for each haplotype, shaded in light gray. All ORs and P-values were obtained 
from a global disease model with an additive term for each haplotype and an interaction 
term for each pair of haplotypes. ”Ref” indicates the reference haplotype for each 
regression model. Bolded values indicate interactions that are significant after multiple 
test correction (P < 0.05/10 = 0.005 for RA, P < 0.05/15 = 0.003 for CeD) 
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Figures 
Figure 1  
 
 
Figure 1. Disease associations of HLA and non-HLA variants. (a) Disease associations of HLA haplotypes with RA, T1D, 
PsV, Ach, and CeD. For each common haplotype, the odds ratio (OR) for heterozygotes is plotted against the OR for 
homozygotes. The dashed line represents a purely log-additive relationship, in which heterozygotes have exactly half the risk 
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of homozygotes (on a log-odds scale). Data points above the dashed line represent haplotypes with a positive dominance 
component, and below the line haplotypes with a negative dominance component. Error bars represent 95% confidence 
intervals. (b,c) De Finetti diagram of the proportion of heterozygotes in relation to the frequency of each HLA haplotype 
(grouped across all diseases), shown separately for (b) cases and (c) controls. The solid line represents the expected 
proportion of heterozygotes under Hardy-Weinberg-Equilibrium. (d) Disease association of 44 known genome-wide RA-
associated SNPs located outside the MHC region, using the same plotting scheme as for panel a. No single SNP shows a 
significant deviation from the dashed line (representing a purely additive disease contribution). (e) De Finetti diagram of 
heterozygote frequency for the same 44 non-MHC SNPs as in panel d, given separately for controls and cases.  
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Figure 2 
 
Figure 2: Non-additive contribution of the HLA to autoimmune disease risk. (a) 
Schematic overview of possible non-additive scenarios. The log-odds for heterozygote 
genotypes can be divided into an additive effect a and a dominance component d, which 
represents the departure from additivity. Depending on the signs of a and d, there are 
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four possible scenarios, represented by red lines. Dashed black lines represent the 
expected log-odds under a purely additive model (d = 0). As an example, the values of a 
and d are indicated for the solid red line (risk variant with positive dominance 
component). (b) Phenotypic variance explained by additive, dominant, and interaction 
effects of HLA haplotypes, respectively, for each disease with a significant non-additive 
HLA contribution (RA, T1D, PsV, CeD). (c) For each common HLA haplotype with 
significant non-additive effect in RA, T1D, PsV, and CeD, we calculated the additive 
(blue bars) and dominance (red bars) components of the log-odds for heterozygotes. 
The dashed line indicates the median of the dominance components depicted in the 
figure. Error bars represent 95% confidence intervals. 
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Figure 3 
    
Figure 3: Interaction effects in the HLA. All common HLA haplotypes (frequency > 
5%) are displayed for (a) HLA-DRB1 (RA) and (b) HLA- DQA1/DQB1 (CeD). Nodes 
represent haplotypes with the color indicating their additive disease contribution, while 
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edges represent significant interaction effects. For both nodes and edges, red color 
indicates disease risk and blue indicates protection, with effect sizes following the scale 
at the bottom. The effect sizes of the interactions are also represented by the width of 
the edges. 
 
 
